Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (351)	9/9/1999 10:56:00 AM
From: Biomaven	Read Replies (3) \| Respond to of 804

Nice looking results. Rather a muted reaction today - maybe we've already had our move related to these results. The piece says that sales for ADD are $500m. I would guess Ritalin is the bulk of this - maybe 75%. Shire's Adderall has been growing fast, mostly because of its longer duration of action than standard Ritalin. Avoiding the trip to the nurse's office is a big deal, which means that longer duration of action is much more significant here than with most drugs. Here's some Thalidomide / HIV news: ama-assn.org Some studies (including this one) have shown small rises in HIV levels when you give T. Anyone heard anything about how the studies of T in AIDS wasting are going? Peter